Pharmaceutical giant Johnson & Johnson could be on the cusp of gaining approval from the FDA for a potential drug that could treat depression and eliminate the costly and time-intensive ketamine treatments that many turn to. Called esketamine, the drug won backing on Tuesday from an outside panel of experts convened by the Food and … Continue reading “Johnson & Johnson May Soon Gain FDA Approval for Blockbuster Depression Drug”
